Tacalyx GmbH has selected its first clinical candidate, TCX-201, and secured €11 million (US$12.8 million) in a first closing of its seed extension round to support the program’s progression through preclinical development. TCX-201 is an antibody-drug conjugate (ADC) against an undisclosed tumor-associated carbohydrate antigen (TACA).